Chemical formula: C₁₉H₁₇F₂N₃O₅ Molecular mass: 405.358 g/mol PubChem compound: 54713659
Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AJ04 | Cabotegravir | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AJ Integrase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VOCABRIA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VOCABRIA Prolonged-release suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VOCABRIA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Cabotegravir is an active ingredient of these brands:
Austria (AT)
Finland (FI)
Israel (IL)
Japan (JP)
Poland (PL)
Romania (RO)
Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
